neuroendocrine

Sanofi pays $110M upfront for late-stage radioligand therapy

Sanofi has made a late entry to the radioligand party, paying 100 million euros for a neuroendocrine tumor drug that is nearing a filing for approval.

Nick Paul Taylor Sep 12, 2024 4:54am

Crinetics growth disorder drug sees ph. 2 carcinoid syndrome win

Mar 13, 2024 9:16am

This is a photo of the Clinical Research Building of the Perelman School of Medicine at the University of Pennsylvania in Phi

Carl June's latest CAR-T work taps llamas for GI cancers

Mar 29, 2022 9:00am

Chi-Med's surufatinib fends off pancreatic tumors in phase 3

Sep 18, 2020 6:05pm

Chi-Med stops pivotal pancreatic cancer trial upon early success

Jan 21, 2020 8:30am

Tiburio launches with $31M and focus on rare endocrine disease

Jan 3, 2019 7:30am